• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.

    12/11/23 5:05:42 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KVSA alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 333-253096
    Issuer: Khosla Ventures Acquisition Co.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 2128 Sand Hill Road
    Menlo Park CALIFORNIA 94025
    Telephone number: 650-376-8559
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Class A Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2023-12-11 By Tara Petta Director
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KVSA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KVSA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KVSA
    SEC Filings

    View All

    SEC Form 15-12G filed by Khosla Ventures Acquisition Co.

    15-12G - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/21/23 9:20:51 AM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Khosla Ventures Acquisition Co. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Khosla Ventures Acquisition Co. (0001841873) (Filer)

    12/12/23 5:25:01 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 25-NSE filed by Khosla Ventures Acquisition Co.

    25-NSE - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    12/11/23 5:05:42 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Khosla Ventures Acquisition Co. Announces Redemption of Public Shares and Subsequent Dissolution

    MENLO PARK, Calif., Dec. 4, 2023 /PRNewswire/ -- Khosla Ventures Acquisition Co. (the "Company") (NASDAQ:KVSA) today announced that it will redeem all of its outstanding shares of Class A common stock that were issued in its initial public offering and not previously redeemed (the "public shares"), effective as of the close of business on December 11, 2023, as the Company will not consummate an initial business combination on or prior to December 8, 2023. Pursuant to the Amended and Restated Certificate of Incorporation, if the Company does not complete its initial business combination by December 8, 2023, then the Company will: (i) cease all operations except for the purpose of winding up,

    12/4/23 5:38:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Mutually Agree to Terminate Business Combination Agreement

    BOSTON and MENLO PARK, Calif., Nov. 15, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by affiliates of Khosla Ventures, LLC, announced today that both companies have mutually agreed to terminate their previously announced agreement and plan of merger (the "Business Combination Agreement"), effective immediately. Both parties decided to terminate the Business Combination based on current market conditions, particularly in the biot

    11/15/21 5:40:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Valo Health and Khosla Ventures Acquisition Co. Announce Additional PIPE Commitments

    BOSTON and MENLO PARK, Calif., Nov. 9, 2021 /PRNewswire/ -- Valo Health, LLC ("Valo"), the technology company using human-centric data and artificial intelligence (AI) powered computation to transform the drug discovery and development process, and Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that the private placement of common stock ("PIPE") investment in connection with their previously announced business combination had expanded from $168.5M to over $200M exceeding initial targets.

    11/9/21 4:00:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/24 4:55:28 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Khosla Ventures Acquisition Co. (Amendment)

    SC 13G/A - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/12/24 12:56:18 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Khosla Ventures Acquisition Co.

    SC 13G - Khosla Ventures Acquisition Co. (0001841873) (Subject)

    2/14/23 4:18:34 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KVSA
    Financials

    Live finance-specific insights

    View All

    Khosla Ventures Acquisition Co. Announces Planned Transfer of Listing to NYSE in Connection with its Proposed Business Combination with Valo Health

    BOSTON and MENLO PARK, Calif., Oct. 28, 2021 /PRNewswire/ -- Khosla Ventures Acquisition Co. (NASDAQ:KVSA) ("KVSA"), a special purpose acquisition company sponsored by an affiliate of Khosla Ventures, LLC ("Khosla Ventures"), today announced that it will voluntarily transfer the listing of its Class A common stock, par value $0.0001 per share ("Class A Common Stock"), from the Nasdaq Capital Market ("Nasdaq") to the New York Stock Exchange ("NYSE") in connection with, and following the closing of, the previously announced business combination (the "Business Combination") with Valo Health, Inc. ("Valo"), the wholly owned subsidiary of Valo Health, LLC ("Valo Health"). The shares of Class A Co

    10/28/21 7:13:00 PM ET
    $KVSA
    Biotechnology: Pharmaceutical Preparations
    Health Care